enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Merck-AstraZeneca breast cancer drug reduces risk of ... - AOL

   www.aol.com/finance/merck-astrazeneca-breast...

   About 5% to 10% of female breast cancer patients have a BRCA mutation, according to the American Cancer Society. When breast cancer is diagnosed early, the five-year relative survival rate is over ...

3. US FDA approves AstraZeneca's breast cancer drug ... - AOL

   www.aol.com/news/us-fda-approves-astrazenecas...

   The Truqap combination enters a competitive market of breast cancer treatments, which include AstraZeneca-Daiichi Sankyo's Enhertu and Gilead's Trodelvy. ... US FDA approves AstraZeneca's breast ...

4. Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug ...

   www.aol.com/latest-trial-setback-astrazenecas...

   Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to the investigator’s choice of chemotherapy.

5. AstraZeneca's breast cancer drug combination fails in late ...

   www.aol.com/news/astrazenecas-breast-cancer-drug...

   (Reuters) - AstraZeneca said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall ...

6. AstraZeneca (AZN) Signs $6.9B Cancer Deal with Daiichi ... - AOL

   www.aol.com/news/astrazeneca-azn-signs-6-9b...

   AstraZeneca (AZN) signs a collaboration deal, potentially costing $6.9 billion, with Japan's Daiichi Sankyo to develop/commercialize a promising cancer treatment.

7. AstraZeneca - Wikipedia

   en.wikipedia.org/wiki/AstraZeneca

   In March 2019, AstraZeneca announced it will pay up to US$6.9 billion to work with Daiichi Sankyo Co Ltd on an experimental treatment for breast cancer. AstraZeneca plans to use some of the proceeds of a US$3.5 billion share issue to fund the deal. The deal on the drug known as trastuzumab deruxtecan sent shares in Japan's Daiichi soaring 16%. [70]

8. National Breast Cancer Coalition - Wikipedia

   en.wikipedia.org/wiki/National_Breast_Cancer...

   Breast Cancer Coalition (NBCC) is a grassroots advocacy organization that combines the power of advocacy, education, policy, and research to unite around the goal of ending breast cancer. It was founded in 1991 by a group of breast cancer survivors, including President Fran Visco.

9. AstraZeneca-Daiichi Breast Cancer Drug Cuts Disease ... - AOL

   www.aol.com/news/astrazeneca-daiichi-breast...

   AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSKYF) Enhertu extended survival by more than six months in patients with a form of advanced breast cancer compared to standard chemotherapy.